HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Direct-Selling Sector Ad Claim Monitor Snares Supplement, Personal Care Product Firms

Executive Summary

A BBB National Programs, Inc. investigative unit tells FTC that Dose of Nature failed to respond to its request to support its CBD oil claims; Utah direct sellers Young Living and doTerra agree to pull or modify drug claims for their essential oil products; HempWorx relabels topical as cosmetic.

You may also be interested in...



Questions Sent To FTC On Supplement Direct Seller Wayal Health Science's Ad Claims

Utah firm failed to respond to Direct Selling Self-Regulatory Council requests for substantiation for ad claims for supplements made in social media posts including “helps fight cancer, depression, and attention-deficit hyperactivity disorder.”

Industry Self-Regulation Review Of Claims Smells Unfair To US Essential Oils Marketer DoTerra

“We firmly believe NAD misunderstood the law and applied the wrong legal standard” says Kirk Jowers, doTerra’s corporate relations chief. But the firm “has little recourse but to comply.”

Young Living Says Consumers Not Swayed By Claim But Expect Its Essential Oils Are ‘Therapeutic’

In NAD review on a challenge by S.C.  Johnson, which markets Caldrea brand essentials oils, Young Living said because consumers are equally as likely to believe the products are therapeutic grade regardless of which image they saw in a survey demonstrates the claim doesn’t impact consumers’ perception of its products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel